Shortage of Natural Resources The Scientific Innovative Power coming from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board.

Slides:



Advertisements
Similar presentations
Ranbaxy Laboratories Limited Differential Pricing & Financing of Essential Drugs Experience with Generic drugs Cecile H Miles Head of Western Europe Division.
Advertisements

Texas & the United Kingdom: Partners in Energy Innovation Azeemeh Zaheer, Vice Consul (Energy - Oil & Gas) International Energy Team, UK Trade and Investment.
Intel and Intel in Ireland Vedvyas Shanbhogue. Intel Snapshot Year founded: 1968 Year founded: 1968 Number of employees: Approximately 94,000 Number of.
Pharmaceuticals Limited India – CIS International Pharma Conference 3-5 th March 2006, Mumbai Prashant Nagre Vice President – API Division.
Your Future Can you see it? What does it look like?
Hale & Tempest The Global Pharmaceutical Industry (MNC & Generic) in Transition Dr. Brian W Tempest The Global Generic Summit – Barcelona,
The Challenges from India in the Global Generic Market Place Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories.
University of Idaho Biotechnology & Biomedical Research Presentation to Legislative Biotechnology Task Force September 7, 2005 By Charles R. Hatch Vice.
The Role of Generics in Reducing the Cost of Healthcare Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited,
Background for Public Hearings October 18, 2004 John Austin, Cherry Commission Policy Director John Burkhardt, Senior Policy Advisor U-M Center for the.
Hale & Tempest Understanding the Strategies Big Pharma are Developing to win in the Global Generics Market Dr. Brian W Tempest Istanbul,
Cross Cultural Workforce Engagement Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India.
Views on the Generics Market Dr Brian Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories, Delhi, India EGA Conference Istanbul,
Structure of Indian Economy. EVEN THOUGH THE WORLD HAS JUST DISCOVERED IT, THE INDIA GROWTH STORY IS NOT NEW. IT HAS BEEN GOING ON FOR 25 YEARS OLD.
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Pharmaceuticals before and after TRIPS Sudip Chaudhuri Professor of Economics Indian Institute of Management Calcutta BRICS Workshop, Aalborg February,
© economiesuisse,, Challenges for Switzerland‘s Foreign Trade Policy Gerold Bührer, Chairman 36th Annual General Meeting 2010 ARAB-SWISS CHAMBER OF COMMERCE.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
Why Promote Science, Technology, Engineering and Maths (STEM) Careers ? STEM Online Module: Getting Started 2013.
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Mumbai – September.
Hale & Tempest India Biotech Briefing Dr. Brian W Tempest IBIZ Conference, NHS Expo Excel London UK 9 March 2011.
Author: Dr Sc Fidel Castro Díaz - Balart World Science Forum Budapest November 2005 Knowledge and Innovation: Challenges and uncertainties for the South.
The New Economic Landscape Brian W Tempest CEO & Managing Director Ranbaxy Laboratories Limited, India The Pharmaceutical Industry in the 21 st Century.
The Emerging High Tech Competitors from Asia, Contrasts between the national systems of innovation and its performance of China and India Professor Sunil.
Hale & Tempest Distribution, OTC & CRAMS Chesapeake Dr. Brian W Tempest UK March 2014.
DIGEST OF KEY SCIENCE AND ENGINEERING INDICATORS 2008 Presentation Slides National Science Board.
Hale & Tempest Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest
1 The Lockheed Martin India Innovation Growth Program
Reflections on the Global Generic Pharmaceuticals Market place Dr. Brian W Tempest Vidya Pratishthan’s School of Biotechnology, Baramati,
Industry-University Relations In Israel Can we do better at this critical time? Moshe Oron, Ph.D. Chief Scientist – KiloLambda Technologies, Ltd. Chairman,
Is Asia the Answer? Dr. Brian W Tempest The 2008 IMS Pharma Strategy Conference New York –12 th February 2008.
Hale & Tempest Global Pharma 2014 Dr. Brian W Tempest Mumbai August 2014.
Sir David King Chief Scientific Adviser to UK Government UK and South Africa: Working in Partnership Cape Town 18 May 2005.
Hale & Tempest Moving Beyond the Commodity Market: What Future is there in added Value Generics, Niche Products and Biosimilars? Dr. Brian W Tempest
Hale & Tempest Inhalation Drug Delivery Conference Dr. Brian W Tempest CpHI Ramada Hotel, Berlin, Germany 11 September 2013.
Partners in Globalisation UK Trade & Investment British Business Group in Mumbai & Pune Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the.
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Zurich – October.
Reflections on the Global Generic Pharmaceuticals Market place Dr. Brian W Tempest CII Pharma Summit Mumbai Thursday November 1 st.
S&T and Innovation Policy in the Republic of Armenia Innovation Programs Division, SCS RA “Development of Coherent Innovation Policy in South Caucasian.
Hale & Tempest India UKIBC Briefing Dr. Brian W Tempest UK India Business Council Manchester 10 March 2011.
1 Maryland Life Sciences Advisory Board William E. Kirwan, USM Chancellor Wednesday September 24, 2008.
Sustaining America’s High Tech Future Innovation and STEM Competitiveness Presented by Marjorie Bynum Vice President, Globally Competitive Workforce The.
Advantages of India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India India Clinical Trials.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
The Challenge from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Manila – 29.
Hale & Tempest Exploring the Structural Changes in the Global Pharmaceutical Marketplace Dr. Brian W Tempest MAPE Fund Managers Conference.
Hale & Tempest A View from India Dr. Brian W Tempest Opinion Formers’ Conference on Intellectual Property for Better Health Wellcome.
India – a growing player Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited Frankfurt – 15 th March’06.
Hale & Tempest Bangladesh Pharma Industry Dr. Brian W Tempest UNCTAD Investment Policy Review of Bangladesh United Nations Palais.
Hale & Tempest Indian Drug Discovery Dr. Brian W Tempest Asia Pacific Technology Network Tuesday 3 April 2012.
Hale & Tempest Mergers, Acquisitions & Alliances in Emerging Markets Dr. Brian W Tempest Generics & Biosimilars, CpHI Conference Istanbul,
Hale & Tempest Doing Business in Russia - the View from Overseas Dr. Brian W Tempest CpHI St Petersburg, Russia 17 April 2014.
Partnering Opportunities in India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Bio-Partnering.
Succeeding in Japan Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India India Japan Initiative.
Tazeem Pasha SelectUSA U.S. Department of Commerce Washington, DC Foreign Direct Investment in the United States 1SelectUSA.gov.
Hale & Tempest How a Major Indian Generic Company went Global Dr. Brian W Tempest Shanghai, China 18 November 2011.
Conference of State Secretaries on Skill Development : Bridging Skills Deficit & Promoting Employability Skill Development : Bridging Skills Deficit &
India – The Pharma Advantage Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India Tokyo –
Hale & Tempest Consultation of Experts to discuss the WHO role in facilitating access to quality, affordable biotherapeutics (monoclonal antibodies & biosimilars.
Hale & Tempest Patents & Health Dr. Brian W Tempest Seminar on the Relationship between Patent Systems and the Availability of Medicines.
Hale & Tempest Biosimilars in Developing Countries: Key Issues Dr. Brian W Tempest Editor, Journal of Generic Medicines Bangladesh.
LOCAL MANUFACTURING : CHALLENGES & OPPORTUNITIES
Trends in the Pharmaceutical Industry and the Potential Impact on Future Innovation and Access to Medicines Dr. Brian W Tempest Pharmaceuticals.
Innovation Development Strategy
Ukraine – An Emerging Software Outsourcing Destination
The New American Dilemma
Learning Outcome: Necessity or Imperative for Excellence
NATIONAL HUMAN CAPITAL FOR SCIENCE, ENGINEERING AND TECHNOLOGY PLAN
Presentation transcript:

Shortage of Natural Resources The Scientific Innovative Power coming from India Dr. Brian W Tempest Chief Mentor & Executive Vice Chairman of the Board Ranbaxy Laboratories Limited, Delhi, India St. Gallen Symposium, St. Gallen, Switzerland Friday, 1 st June 2007

Asia’s Share of the World GDP (at PPP in %) Year China 17% 9% 5% 5% 12% India 12% 8% 4% 3% 5% Japan 2% 3% 3% 8% 7% Rest of Asia 7% 5% 7% 9% 13% Total Asia 38% 25% 19% 25% 37% Source – WEF - was 59% in 1820 with India 16%, China 33%

Davos Source – FT

The Productivity Advantage Indiaa usa Pharma view USA 1 chemist Better education x chemist 70 hours/week Longer working time x hours/week $ 800 monthly Lower cost x 20 $ 12,000 monthly Sources: IPHMR Conferences, New Delhi August 2004

 Japan - by % > 65 years from 19% in 2005  China - one child families, get older before becoming wealthy - labour costs will rise owing to labour shortage  India - India already has the youngest labour force in the world - source of the extra needed global workforce - India will pass China in total population in By 2013 India will have more young workers than China The Ageing Advantage Working Population, years In millions

The R&D Investment Advantage Most attractive R&D Investment locations: Ranked 3 rd - China, USA, India, Japan & UK Source – UNCTAD 2005 Reasons why India:  Qualified Scientists & Engineers  Global India players with Alliances  English speaking  TRIPs compliant – first patent March 2006  IIT, IIM & other scientific institutions Source – UNCTAD 2005

 4 th largest reservoir of Scientific Manpower (2 nd largest English speaking)  3m graduates pa, 115k MSc Chemistry (3.5k UK), 215k Eng (222k USA) Physics the most popular subject  Lead by a Nuclear Scientist as President – remote sensing satellite technology, 1/6 countries  PCT application ranked 3 rd – Kor, Chi, Ind, Sin, RSA  “US & Europe will not dominate Science, Maths, IT industries” – Mr. Bill Gates The Science Natural Resources Advantage

Science Natural Resources in EU “This means that when pupils are in a science laboratory their experience is unsafe, unsatisfactory or uninspiring for 65% of the time.” Source: Royal Society of Chemistry, Policy Bulletin – Spring 2006 UK “A” Level entries:Closed UK University % change Chemistry Departments: Physics : 32,059 28, % Dundee Kings Chemistry: 40,856 38,851 -5% Surrey Exeter Maths: 67,036 52, % Lancaster Queen Mary Computing: 19,099 7, % Source: Daily Mail – 11 August 2006 Only pupils at private schools can take physics, chemistry & biology separately Source: Times, 9 th November 2006

Number of Higher Education Institutions 05/06 18, % 00/01 11,412 90/01 5,932 80/01 4,861 Source: Indian University Grants Commission Science Natural Resources in India Number of Students enrolled in Higher Education Institutions 05/06 10, % 00/01 7,500 90/01 4,000 80/01 3,000 Source: Indian University Grants Commission Number of Institutions courses 05/06 99/00 Pharmacy % Medicine % Physiotherapy % Source: Pavan Agarwal (2006) based on data from professional councils PhD Degree awarded in Science 03/ % 00/ / (USA 03/04 25,000) Source: Indian University Grants Committee

The Science Natural Resources Advantage Engineers/Science graduates p.a – India 0.7m, China 0.5m, EU 0.5m, USA 0.4m, Japan 0.3m

 Microsoft Global Development Centre (GDCI)  Microsoft Global Services (MGSI)  Microsoft Global Technical Support Centre (GTSC)  Microsoft Systems Research (MSRI)  Microsoft India Development Centre (MIDC) Investment by Microsoft in India

The Pharma Plants Advantage Active Pharmaceuticals Facility, MohaliDosage Forms Facility, Paonta Sahib

Generics – API’s USA DMF filings by India Source: Crisil / US FDA / J P Morgan % Share of USA DMF filings India China % 9% % 10% % 14% Q1’07 48% 17% Source: US FDA / J P Morgan, 2 nd May 2007 Source: US FDA, Credit Suisse

Generics Rankings Source: UBS, Businessworld, 30 th October 2006

Discovery – Local vendors available in India to Support Discovery Research Vendor Availability India China Analog preparation4125 Combinatorial chemistry377 Analytical chemistry377 Structural chemistry265 Assay development262 Computer drug design2613 High throughput Screening112 Bio informatics137 Genetically modified animals03 Basic molecular biology1325 Source – BCG, ‘Looking Eastwards, September 2006’ * Out of 90 vendors in October 2005

A race to prosperity

The Tempest Crystal Ball – India & China Post TRIPs new products will dry up in India by Under this pressure Indian companies will adopt different business models The global generic industry will be dominated by India Discovery companies will continue to be attracted to India China will be perceived to be stronger in biology/ toxicology Alliances between Western Biotech and Indian companies will expand It will be India & China - and not India or China.

Potential Challenge – Asian Flu* *50% of world chickens bred in Asia

Potential Challenge – Infrastructure Source – Manmohan Singh “Our greatest potential will be realised only if we can ensure that our Infrastructure does not become a severe and critical handicap”

CO 2 emission - % of World total in USA23% EU 2517% China14% Russia7% Japan5% India4% – source: WRI, EIA Potential Challenge – Climate Change

Asia economic strength is returning to levels seen in the past Many advantages for India – Demographics, Education India is a global strategic asset for developed markets Some “Challenges” – infrastructure, climate change The current feeling in Indian Boardrooms is that a turning point has been reached, a tipping point has been passed and India’s time has arrived India is a rich location for future alliances MNCs will dip in& out of India & China, using their individual strengths “China & India represent the future of Asia and quite possibly the future for the global economy” – Steve Roach, Morgan Stanley Summary The Scientific Innovative Power coming from India

Thank You